| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparison of vials with ampoules for the storage of biological reference materials
|
Matejtschuk, Paul
|
|
2005
|
33 |
2 |
p. 63-70
8 p.
|
artikel
|
| 2 |
Aims and Scope/Editorial Board/Publishing Details
|
|
|
2005
|
33 |
2 |
p. CO2-
1 p.
|
artikel
|
| 3 |
Anti-A and anti-B activity in batches of different intravenous immunoglobulin products determined using a direct haemagglutination method
|
Thorpe, Susan J.
|
|
2005
|
33 |
2 |
p. 111-116
6 p.
|
artikel
|
| 4 |
Cancer Vaccine Consortium – potency testing workshop, San Francisco, November 8, 2004
|
|
|
2005
|
33 |
2 |
p. 123-
1 p.
|
artikel
|
| 5 |
Decreased sensitivity to diphtheria toxin of Vero cells cultured in serum-free medium
|
Piersma, S.J.
|
|
2005
|
33 |
2 |
p. 117-122
6 p.
|
artikel
|
| 6 |
Design of a UV-C irradiation process for the inactivation of viruses in protein solutions
|
Li, Qiangyi
|
|
2005
|
33 |
2 |
p. 101-110
10 p.
|
artikel
|
| 7 |
Microbial contamination of cell cultures: A 2 years study
|
Mirjalili, A.
|
|
2005
|
33 |
2 |
p. 81-85
5 p.
|
artikel
|
| 8 |
[No title]
|
Lubiniecki, Anthony S.
|
|
2005
|
33 |
2 |
p. 129-
1 p.
|
artikel
|
| 9 |
Part I: Historical perspective of vaccine potency tests
|
|
|
2005
|
33 |
2 |
p. 123-124
2 p.
|
artikel
|
| 10 |
Part II: Dendritic cancer vaccine potency tests
|
|
|
2005
|
33 |
2 |
p. 124-125
2 p.
|
artikel
|
| 11 |
Part III: Live whole cell cancer vaccine potency tests
|
|
|
2005
|
33 |
2 |
p. 125-126
2 p.
|
artikel
|
| 12 |
Part IV: Peptide/Protein cancer vaccine potency tests
|
|
|
2005
|
33 |
2 |
p. 126-127
2 p.
|
artikel
|
| 13 |
Part V: Viral cancer vaccine potency tests
|
|
|
2005
|
33 |
2 |
p. 127-128
2 p.
|
artikel
|
| 14 |
Potency estimation of measles, mumps and rubella trivalent vaccines with quantitative PCR infectivity assay
|
Schalk, J.A.C.
|
|
2005
|
33 |
2 |
p. 71-79
9 p.
|
artikel
|
| 15 |
Professor Fred Brown, O.B.E., F.R.S, 1925–2004
|
|
|
2005
|
33 |
2 |
p. 61-62
2 p.
|
artikel
|
| 16 |
SARS-coronavirus (SARS-CoV) and the safety of a solvent/detergent (S/D) treated immunoglobulin preparation
|
Rabenau, H.F.
|
|
2005
|
33 |
2 |
p. 95-99
5 p.
|
artikel
|
| 17 |
TSE clearance during plasma products separation process by Gradiflow™
|
Wang, Kailing
|
|
2005
|
33 |
2 |
p. 87-94
8 p.
|
artikel
|
| 18 |
Workshop summary
|
|
|
2005
|
33 |
2 |
p. 128-
1 p.
|
artikel
|
Tijdschrift beschrijving